Natural Health Trends Corp. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. Amounts are in U.S. dollars; financial figures below are in millions unless otherwise noted.
Business context
Natural Health Trends sells personal care, wellness and “quality of life” products through direct selling and e-commerce. The company reported 46,860 active members at quarter-end, down from 49,420 at March 31, 2021 and 54,370 a year earlier. Hong Kong generated 78.7% of Q2 net sales; substantially all of that revenue came from products delivered to members in China.
Financial performance
| Metric | Q2 2021 | Q2 2020 | First half 2021 | First half 2020 |
|---|---|---|---|---|
| Net sales | $16.152 | $16.404 | $29.621 | $31.352 |
| Gross profit / margin | $12.218 / 75.7% | $11.587 / 70.6% | $22.432 / 75.7% | $22.021 / 70.2% |
| Operating income (loss) | $0.385 | $0.183 | $0.605 | $(1.265) |
| Net income (loss) | $0.229 | $0.034 | $0.382 | $(0.539) |
| Diluted EPS | $0.02 | $0.00 | $0.03 | $(0.05) |
Q2 operating margin was 2.4% and net margin 1.4%; first-half operating margin was 2.0% and net margin 1.3%. Gross margin improvement reflected lower logistics costs, fewer product promotions and higher administrative-fee revenue. Q2 SG&A rose to $4.9 million from $4.3 million, primarily due to holding the company’s first major event since the pandemic began.
Cash flow, balance sheet and capital returns
- First-half operating cash flow was $0.548 million, versus cash used of $1.018 million in 2020. Investing cash use was $0.147 million; financing cash use was $4.570 million, entirely dividends.
- Cash and cash equivalents were $88.1 million at June 30, down from $92.4 million at year-end; including restricted cash, the balance was $88.6 million. The cash decrease was primarily attributable to dividends.
- Working capital was $72.4 million and the current ratio was 4.1:1. Total liabilities were $38.0 million. The filing reports operating lease liabilities of $3.7 million and does not report interest-bearing borrowings.
- The company paid $0.20 per share in each of the first two quarters. The board declared another $0.20 quarterly dividend on August 2 and management expected quarterly dividends to continue for the remainder of 2021, subject to board discretion. $21.9 million remained under the share repurchase authorization.
Changes, outlook and risks
- Sales declined 2% year over year in Q2 and 6% for the first half. First-half Hong Kong sales fell $2.1 million; sales outside Hong Kong increased 6%.
- Management attributed pressure to COVID-related restrictions and disruption in China, the challenging Chinese health-products regulatory environment, and supply-chain bottlenecks. Q2 deferred revenue increased, including $3.7 million for unshipped orders and unredeemed vouchers; management cited a $1.6 million quarter-on-quarter increase in these items, partly due to product shortages.
- Management said near-term financial performance could remain adversely affected. It considers existing liquidity and operating cash flows adequate for normal operations and commitments for the foreseeable future.
- Approximately 93% of net sales came from outside the Americas. The filing highlights exposure to China and Hong Kong, member attrition, COVID-19, political and regulatory developments, foreign exchange, product and supplier concentration, and direct-selling compliance.
- The SEC is conducting a non-public investigation concerning possible federal securities-law violations relating to trading in the company’s securities and/or public disclosures. The company says it is cooperating; the outcome and timing are uncertain. The filing separately reports no legal proceedings under Part II, Item 1.
- A new risk factor addresses privacy, data protection and information security. China’s Data Security Law was promulgated in June 2021 and was scheduled to take effect in September 2021.
- Management concluded disclosure controls were effective as of June 30, 2021; no material change in internal control over financial reporting was reported.
Most important facts for investors to verify
- Whether active-member losses stabilize and whether Hong Kong/China sales recover.
- Whether deferred orders and vouchers convert to shipped sales, and whether supply constraints persist.
- Developments and potential consequences of the SEC investigation and evolving China regulatory requirements.
- Whether operating cash flow can support recurring dividends and other capital returns if profitability remains modest.